PSMA ADC Clinical Trials

TrialTitleStudy Record DetailPhaseSponsor/Colaborator
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate CancerNCT01414283Phase IProgenics Pharmaceuticals, Inc
An Open-label Treatment Extension of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT02020135Phase IIProgenics Pharmaceuticals, Inc
A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT01695044Phase IIProgenics Pharmaceuticals, Inc
PSMA ADC 1301EXTExtended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate CancerNCT01414296Phase IProgenics Pharmaceuticals, Inc
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)NCT01856933Phase IIHeinrich Elinzano, MD (Brown University); Progenics Pharmaceuticals, Inc; Rhode Island Hospital; University of California, San Diego, CA; Thomas Jefferson University, Montefiore Medical Center, University of Texas.

Last Editorial Review: July 15, 2016